Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4427MR)

This product GTTS-WQ4427MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4427MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2912MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ8620MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ7926MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ8583MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ15324MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ9268MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ14005MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ11540MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGA031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW